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Abstract
Body mass index (BMI) and simple counts of weight are easy and available tools in the clinic and 
in research. Recent studies have shown that cancer patients with low-normal BMI (or those with 
weight loss) have worse outcomes than obese patients. These results suggest that obesity has a 
protective effect and has been termed the ‘obesity paradox’. In this commentary, we discuss 
hypothetical explanations and take a step beyond BMI or simple weights alone to present other 
useful and more specific body composition metrics such as muscle tissue mass, visceral, and 
subcutaneous fat mass. Body composition is highly variable between individuals with significant 
differences seen between various races and ages. Therefore, it is critical to consider that patients 
with the exact same BMI can have significantly different body compositions and different 
outcomes. We encourage further studies to examine body composition beyond BMI and to use 
other body composition metrics to develop individualized treatments and intervention strategies.
The usage of Body Mass Index (BMI) to characterize the different body/obesity types has 
been common place for decades, yet limitations persist in its use. BMI is a calculated value 
(body weight (Kg) divided by square height (m2)) and exists as an easy and simple tool in 
the clinic and in research to differentiate and categorize patients as underweight 
(BMI<18.5), normal weight (18.5–24.99), overweight (25–29.99), and obese (>30). In a 
large scale British study (1) (over 5 million individuals), BMI was significantly associated 
with 17 of 22 cancers, among them liver, colon, and postmenopausal breast cancers. 
Although obesity in the general population is associated with an increased risk of death(2), 
there are conflicting reports about the relationship between obesity and mortality among 
individuals with cancer and several other chronic diseases.(3–5) This phenomenon, known 
as the “obesity paradox”, suggests a potential protective effect in overweight and mildly 
obese patients. Mortality curves for BMI for any population are usually U-shaped (with 
increased mortality at both ends), but the debate primarily lies as to where the nadir for 
mortality exists.(6) Two studies in this issue evaluate the association of weight changes in a 
large cohort of patients with two common early stage cancers: breast and colorectal. 
Cespedes et al concluded that weight loss and gain are equally common after breast cancer, 
and weight loss is a consistent marker of mortality risk.(7) Meyerhardt et al demonstrated 
that weight loss after a colorectal cancer diagnosis was associated with worse cancer-
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specific and overall mortality.(8) The third study by Greenlee et al is a pooled analysis of 22 
clinical trials from SWOG (n=11,724) and showed that BMI≥25kg/m2 was associated with 
better overall survival among men (HR=0.82; P=.003), unlike in women (HR=1.04; P=.86).
(9) Both methodological and physiological explanations exist for explaining this 
phenomenon and these results, but what is the clinician supposed to recommend patients 
today? Should we enter the clinic tomorrow and tell our patients to gain weight? Or stop 
encouraging them to keep within the “normal” range of BMI?
Many hypothetical explanations exist that help explain the obesity paradox. One of them is 
the collider stratification bias (a form of selection bias) that may in part explain the 
phenomenon,(10, 11), but this unlikely fully accounts for the observed findings. (12) The 
increased nutritional reserves provided by excess fat stores and higher lean body mass in 
obese patients(13) may provide an added advantage during periods of acute illness.(14) 
Additionally, it is plausible that lower BMI categories disproportionately include sicker 
patients, and in turn, are at higher risk of mortality. The loss of weight could also be 
associated with smoking and related to other comorbidities which can be another 
confounder. (15) Weight loss amongst even the general older adult population is associated 
with frailty and an increased mortality risk.(16, 17) Weight loss at a cancer diagnosis is often 
a marker of more aggressive cancer and/or advanced disease. Even in earlier stage patients, 
lower weights may be a marker of subclinical tumor activity. Changes in weight can be seen 
over 6 months prior to a cancer diagnosis and appreciable subclinical impacts on lipid 
metabolism can start as early as two years before a diagnosis is made.(18) Of note, the 
impact of cancer on body metabolism and cachexia varies greatly by tumor type and stage, 
and clearly cancer can have a significant impact on weight and the distinction between 
intentional and non-intentional weight loss is a major issue.(19)
Although BMI and simple weight measurements are the easiest and most available clinical 
measures and have helped gain an enormous amount of knowledge regarding the 
relationship of obesity and cancer prevention as well as cardiovascular diseases (20), one 
major flaw and limitation of both are their inability to differentiate fat and muscle mass. 
Body composition and BMI differ considerably between different ethnic groups (see table 
1). While African Americans have higher BMI on average, they also have higher lean body 
mass (LBM) and subcutaneous fat with lower visceral fat, while Caucasians generally have 
higher visceral fat and lower subcutaneous and LBM. Of note, south Asians have almost 
‘normal’ average BMI, but have a lower LBM and higher visceral fat than African 
Americans.(21) Age is another factor associated with alterations in body composition and 
with age there is a decrease in muscle mass and strength, known as sarcopenia.(22–24) The 
assumption that adults have an optimal weight range (corrected for height) is probably 
sound, but assuming that this is the same for all individuals regardless of ethnicity, age, and 
health status is challenging. Furthermore nutritional status is also an important component, 
and BMI/weight is not always an adequate indicator of nutrition status. (25)
In oncology, body composition has been shown to have a substantial impact on outcomes.
(26, 27) Many studies demonstrate an association between different indices and prognosis in 
different tumors. Table 2 highlights the multitude of body measures used in the literature, 
their measurement calculations, and some example findings in oncology. In a recent meta-
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analysis, sarcopenia (low muscle mass) derived from CT imaging was significantly 
associated with inferior survival across tumor types and disease stages.(27) Assuming the 
impact of weight is the same regardless of the degree of adiposity or skeletal muscle ignores 
a growing body of evidence within oncology and elsewhere. Patients with lower muscle 
mass have higher rates of surgical complications,(28) which may delay the preferable timing 
of adjuvant treatment initiation, a known factor for inferior outcomes.(29) In addition, 
sarcopenic patients have higher rates of treatment toxicity (26, 30, 31) that, in turn, can 
cause dose delays and reductions, resulting in lower dose intensity and worse outcomes.(32, 
33) Also, recent evidence in a large cohort of patients with early stage colorectal cancer 
demonstrated that decreased muscle mass and attenuation was significantly associated with 
markers of systemic inflammation, but neither have correlation with BMI. This highlights 
the significant interaction of body composition and the inflammation process that can impact 
metabolism, weight loss, and body resistance to tumor growth.(34) Although body 
composition analysis is much more accurate in quantifying muscle mass and adiposity, it is 
not yet a standard component of clinical care in oncology or elsewhere.
In cancer, as well as other diseases, physical activity should be discussed alongside body 
composition as physical activity has an important influence on the prevention of cancer (35) 
and survival after diagnosis. (36) Physical activity can also increase muscle mass and 
augment metabolic and hormonal axes (37), as well as be used as an important intervention 
tool.
The evolving field of personalized medicine in oncology is playing an increasing role in 
cancer prevention, diagnosis, prognosis, and therapeutics.(38) In the last decade there has 
been great progress in understanding tumor characteristics including proliferation rate, 
mutation load and type, and when utilized to guide cancer therapy there is potential for 
improved survival.(39, 40) The impact of host factors remains underappreciated and poorly 
understood. Personalized medicine should go beyond only tumor genetics and 
pharmacogenomics, but should also include a patient’s body composition, physical function, 
and comorbidities. These factors can also greatly impact treatment decisions and drug 
dosing with an overall impact on outcomes. In the same way that treatments in oncology are 
rarely one size fits all, the “right” weight for a given individual is likely dependent on a 
multitude of factors and should also be individualized.
The studies in this issue highlight the importance of body measures in cancer and add to the 
growing literature in this emerging field. So what should clinicians be telling their patients 
regarding weight loss or weight gain after a cancer diagnosis? The answer is complex and 
not yet clear with many unresolved questions remaining. Is weight loss a sign for tumor 
activity, and if it is, can we even reverse that process? Will future randomized control trials 
with the goal of achieving the “right” BMI improve survival? Will it be the right BMI or the 
right body composition? Is it the amount of LBM or the ratio between the LBM to fat 
(adiposity/muscularity ratio)? Is it the size/quantity of muscle or as recent evidence has 
shown, the quality of muscle (radiodensity) that impacts survival.(41, 42) To date we have 
more questions than answers, and we need to gear up with focused studies about the impact 
of body composition on different outcomes and step forward with intervention and 
prevention strategies.
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